Investors

Investor Information

Press Releases

info@cordexpharma.com

Duska Therapeutics, Inc. has been renamed as Cordex Pharma, Inc. (Symbol: CDXP.OB)

April 8, 2009	Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers
March 4, 2009	Cordex Pharma Files ATPace Formulation Patent
February 23, 2009	Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
February 18, 2009	Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace
February 13, 2009	Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
February 11, 2009	Cordex Pharma Forms Heart Failure Medical Advisory Board
January 28, 2009	Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
January 23, 2009	Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29
November 20, 2008	Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
November 20, 2008	Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
November 18, 2008	Duska Therapeutics Sets Third Quarter 2008 Business Review and Program Update Call
November 10, 2008	Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
October 29, 2008	Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
October 23, 2008	Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
August 21, 2008	Duska Therapeutics Provides Clinical Program Review and Reports Second Quarter 2008 Financial Results
August 19, 2008	Duska Therapeutics to Present at Noble Financial Equity 'M.A.D. MAX' Conference on Tuesday, August 19th at 1:30 p.m. PDT
August 12, 2008	Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace Protocol Synopsis
July 23, 2008	Duska Therapeutics Submits Phase 3 ATPace Protocol to FDA for Comment
June 26, 2008	Duska Therapeutics Obtains Standard & Poor's Listing
June 11, 2008	Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
June 9, 2008	Duska Therapeutics Retains Redington for Investor Relations
May 14, 2008	Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
April 25, 2008	Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace
April 15, 2008	Duska Therapeutics Sets Annual Meeting of Shareholders for June 27
April 2, 2008	Professor Riccardo Polosa Joins Duska Therapeutics' Scientific Advisory Board
March 11, 2008	Duska Therapeutics Plans Meeting with the FDA on ATPace
February 20, 2008	Duska Therapeutics to Present At Winter Global Equities Conference
February 7, 2008	Study Shows ATP Improves Motility of Sperm From Infertile Males
January 29, 2008	Duska Therapeutics Completes Corporate Relocation to La Jolla
November 13, 2007	Duska Therapeutics CEO Television Interview
November 1, 2007	Duska Therapeutics, Inc. Announces Engagement of RedChip Companies, Inc. to Lead Public and Investor Relations
October 31, 2007	Duska Therapeutics Appoints Dr. Alan J.Tuchman to the Board of Directors
October 18, 2007	Duska Therapeutics Appoints Shepard Goldberg and Steven Dinh as Board Directors
October 11, 2007	Duska Therapeutics Appoints H. David Coherd to the Board of Directors
October 3, 2007	Duska Therapeutics Names Dr. James S. Kuo as Chief Executive Officer
October 1, 2007	Duska Therapeutics Completes $5.75 Million Private Equity Financing